Clinical Trials Browser

Interventional × navitoclax × Lymphoid × Clear all

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00788684 2025-02-20

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Phase 1 Completed

29 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

NCT05740449 2024-06-21

HEM-iSMART A

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06210750 2024-05-17

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00481091 2023-06-13

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1/2 Completed

60 enrolled 32 charts

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03181126 2021-10-14

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Phase 1 Completed

69 enrolled

LymphoidOther hematologic neoplasm

Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05054465 2021-09-23

ITALLI001

Phase 1/2 Not yet recruiting

48 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00406809 2021-08-02

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Phase 1/2 Completed

81 enrolled

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Leukemia, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01121133 2017-11-21

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

Phase 1 Completed

12 enrolled

Lymphoid

Lymphoma

NCT01087151 2016-11-02

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

118 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01423539 2016-11-02

NAVIGATE

Phase 2 Withdrawn

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00868413 2013-06-07

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Completed

32 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01021358 2010-12-20

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Phase 1 Completed

12 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00743028 2010-10-07

Assess the Oral Bioavailability of New ABT-263 Formulations

Phase 1 Completed

36 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

HEM-iSMART A

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

ITALLI001

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

NAVIGATE

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Assess the Oral Bioavailability of New ABT-263 Formulations